The financial management system for the PIN is based on an international financial settlement process. Host countries report on planned expenditures under their responsibility for approved projects. After approval of the forecasts by the investment committee, the international staff calculates the amounts to be paid by each country and to receive from each host country. Other calculations would determine the amounts of payments, currencies and the country or NATO agency that will receive the funds. The old Mutual Recognition Agreement (MRA) came into force on 29 May 2004. It allowed regulators to rely on inspections of good manufacturing practices (GMPs) in the affected areas, not to test batches of medicines entering Japan from EU countries and, conversely, to exchange information on inspections and quality defects. This important agreement, which updates the 1998 Mutual Recognition Agreement, reinforces the dependence on know-how and mutual inspection resources. The mutual benefits to the EU authorities and the FDA are: to take charge of this agreement, teams from the relevant EU authorities, the European Commission, the European Medicines Agency and the US FDA have worked hard to review and evaluate the surveillance system concerned. Is it necessary for a drug manufacturer to follow good distribution practices (GDP) or is it the role of wholesalers and distributors? >> GDP requirements are very similar to the GMP requirements for manufacturers with regard to drug storage. Manufacturers must meet the product storage requirements set out in the GMP.
In addition, when they are responsible for the distribution of their products, they must meet THE requirements of GDP; This includes storing and transporting their products according to the product label to ensure their safety throughout the supply chain. In accordance with Chapter 2, paragraph 2.2. Each wholesaler must designate a person responsible for GDP. Are there circumstances in which the manufacturer of the drug must identify a person responsible? >>EU manufacturing authorization includes wholesale licence, which is why a manufacturer can legally market its products and the QP mentioned in the manufacturing licence may assume responsibility for the storage and distribution of the product. Therefore, the manufacturer is not obliged to name a PC. However, depending on the organizational structure and complexity of the transaction, the entity may appoint a person responsible for the distribution of the product. Each wholesaler must obtain an authorisation issued by the competent authority of the Member State in which the wholesaler is based. Are permits required for a storage or storage building? >> Yes, if a product is stored in a warehouse, that facility must be included either in the manufacturer`s license (manufacturing license) or in the wholesale license.
In the EU, you cannot store products in an unauthorized establishment (except at the place of distribution for a short period of time, for example. B 24 hours) Each manufacturer of a drug must monitor and monitor the supply chain (wholesalers, carriers and distributors, etc.) of finished products. Is it the responsibility of the qualified person of the manufacturer of the drug? >> The owner of the product in the supply chain is responsible for its management in the supply chain, if the manufacturer owns the product in the supply chain, then his PS is normally responsible for the product in the supply chain. Of course, this responsibility can be delegated to another PQ or a PR, but the ultimate responsibility remains in the hands of the PQ. I have heard of the request that the drugs not be stored for more than 24 hours, because in this case the institution should be licensed.